Overview
PVLA market data
Price History
PVLA price chart · 1M
- O
- 156.04
- H
- 156.04
- L
- 150.00
- C
- 150.14
- Vol
- 11,662.00
- Source
- US equities market feed
- Observed
- Aug 27, 2026, 12:00 AM
- Cadence
- Five-minute page cache; daily and stored hourly bars
- Status
- fresh
Key Stats & Performance
- Open
- $156.04
- Previous Close
- $154.49
- Day High
- $156.04
- Day Low
- $150.00
- 52 Week High
- $160.05
- 52 Week Low
- $100.19
- 7 Day Return
- +5.46%
- 30 Day Return
- +5.29%
- 90 Day Return
- +27.11%
- 1 Year Return
- +22.48%
- Daily Notional Volume
- $1.8M Latest daily bar volume multiplied by its closing price.
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$7.62 Diluted earnings per share over the trailing twelve months.
- Beta
- -0.23 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -39.7% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $49.13 – $161.38 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $2.2B · P/B 44.27 · P/S 54.74.
Company News
Full Transcript: Palvella Therapeutics Q2 2026 Earnings CallBenzinga · Aug 4, 2026, 1:52 PM
Palvella Therapeutics Q2 EPS $(1.52) Misses $(1.14) EstimateBenzinga · Aug 4, 2026, 11:30 AM
8-K filing — PALVELLA THERAPEUTICS, INC. (PVLA)SEC EDGAR · Aug 4, 2026, 11:30 AM
Hasbro, Utz Brands, Park Aerospace And Other Big Stocks Moving Higher On TuesdayBenzinga · Jul 21, 2026, 2:37 PM
Palvella Therapeutics Submits First Module Of Rolling NDA To FDA Seeking Approval Of QTORIN 3.9% Rapamycin Anhydrous Gel For Treatment Of Microcystic Lymphatic MalformationsBenzinga · Jun 29, 2026, 11:40 AM
Palvella Therapeutics Announces FDA Rolling Review Of Its New Drug Application For Qtorin Rapamycin For The Treatment Of Microcystic Lymphatic MalformationsBenzinga · Jun 22, 2026, 11:40 AM